Avitia
AI‑powered on‑site NGS diagnostics that accelerate cancer mutation detection and treatment selection.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $50M
AI Company Overview
AI‑powered on‑site NGS diagnostics that accelerate cancer mutation detection and treatment selection.
Oncology
Technology Platform
AI‑enhanced next‑generation sequencing platform that combines targeted multi‑gene panels with machine‑learning analytics for on‑site liquid‑biopsy and tissue diagnostics.
Opportunities
Expansion into new geographic markets and reimbursement pathways, plus addition of broader oncology panels, can drive significant revenue growth.
Risk Factors
Regulatory approvals, data‑privacy compliance, and competition from larger diagnostics firms could hinder market adoption.
Competitive Landscape
Competes with Guardant Health, Foundation Medicine, and Illumina; differentiates through on‑site AI‑driven testing and cost‑effective deployment in underserved regions.